Open in interactive viewer → charts, metric popovers & call review

CorMedix Has $355 Million of Cash and a $58 Million Enterprise Value

The 2027 DefenCath reimbursement floor that management spent four quarters promising quietly became a deferral — and the Heron deal is the answer to a question investors had not finished asking.
CRMD · Earnings Call · 2026-11-12

The Cliff, Minus the Makeup

CorMedix reported third-quarter revenue of $54.5 million against $104.3 million a year ago, and adjusted EBITDA of $3.1 million against $71.9 million. Those are the headline numbers. The more revealing number is buried one level down: DefenCath revenue was $17.2 million, but $5 million of that was a favorable change in estimate on Medicaid rebate and product return allowances. The underlying quarterly run rate is closer to $12 million. This is not a one-off. A favorable change in estimate now sits near the top of the company's keyword rankings for the first time — but the mechanic has quietly become a recurring feature, following the $9 million "good guy" in the first quarter and a similar true-up in the second. Serge Belanger of Needham asked the question nobody else wanted to: with $5 million of the $17.2 million coming from an allowance release, should investors think of $12 million as the base going forward? Joe Todisco's answer was one word of qualification and one of confirmation: “tentatively, yes. I think it would be a little bit of a notch up but that is probably the right way to look at it.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-11-12 That is the entire quarter in miniature. A ~$12 million-per-quarter product has replaced one that was running north of $90 million. Total revenue has gone from $129 million to $102 million to $54.5 million across three quarters, and gross margin has compressed from a 95.4% peak to 75.7%. The product did not lose patients — the price did.

The Floor That Vanished

For four consecutive quarters, management sold investors a specific form of comfort: a floor under 2027. In March, Todisco framed it as a promise of durability — “we wanted to give investors comfort that there is at least a base business level of DEFENCATH, which we expect to see price appreciation and hopefully stable volumes” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-03-05. In May he went further, with a stated ambition to revise upward: “Right now, I think I'm comfortable saying we're affirming the guidance we put out previously for 2027... would love to be in a position later this year, early next year to take that guidance upwards.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-05-14 Seven months later, the floor is gone.

In that regard, we are deferring 2027 DefenCath guidance at this time and anticipate being able to update investors in early 27.

Joseph Todisco, Chairman and Chief Executive Officer · 2026-11-12
The mechanism behind the retreat is the post-TDAPA arithmetic. CMS finalized a quarterly reset, beginning at $8.30 for the first quarter of 2027. Management expects every quarter of 2027 to clear today's $2.37 rate and the full-year average to land at something like double it — but also concedes the annual average will be below $8.32. The critical, under-appreciated wrinkle: the quarterly reset is fed by utilization and pricing data only CorMedix possesses. “We have not shared that data with any customer or third party, we believe third party projections of the quarterly path are subject to significant uncertainty.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-11-12 The company is, literally, the sole source of the inputs that determine its own reimbursement. Todisco's explanation — that CMS uses the timing of rebate payments rather than accruals, and that long-dated volume-incentive rebates will land in different periods than financial statements imply — is a real accounting point, and also a warning that sell-side models built off the income statement will be wrong in both directions. The offset is Medicare Advantage, where the contractual framework is described as "largely final" but operationalization is not — the aircraft-carrier metaphor returns verbatim from prior calls. Until then, fee for service patients is now the company's single highest-ranked keyword, which is itself telling: the narrative has moved from growth to retention of a shrinking, price-reset population.

The Heron Answer

Heron is the largest single-quarter momentum gainer in CorMedix's keyword history, and it is not hard to see why the company reached for it. Roughly $150 million of trailing net product revenue, $125-150 million guided for pro forma 2027, roughly doubling the non-DefenCath base, and $45-60 million of annualized operating synergies by the end of 2027. Structurally, the deal is sensibly built: up to $55 million of consideration is contingent on ZYNRELEF hitting 2028 net sales milestones, with royalty kickers on CINVANTI and SUSTOL above threshold. But step back and look at what the market is actually pricing. CorMedix ended the quarter with $355.2 million in cash. Its market capitalization is approximately $413 million. That leaves an enterprise value close to $58 million for a business guiding $325-345 million of 2026 revenue and $130-140 million of adjusted EBITDA. Price to revenue has collapsed to 1.3x, down more than 80% year over year. That is not a haircut for uncertainty. It is a verdict that the cash is the asset and the operating business is optionality. The tape agrees. The shares are down 44% over the last 90 trading days, from $8.67 in early July to roughly $4.84, and the drawdown is still in force into the print. Management bought $150 million of revenue with a balance sheet the market is refusing to credit. The Heron bet is, in effect, a wager that a diversified acute-care institutional platform is worth more than the sum of its parts — a claim Melinta has been making for four quarters without the multiple confirming it.

What Went Quiet

The RESPECT study was one of the loudest themes in the company's history and is now the single biggest keyword decliner. That is the good kind of silence: it has been replaced by priority review, an accepted sNDA with a first-quarter-2027 action date and commercial preparation for the second half of the year. That is a genuine, dated catalyst in a call otherwise short on them. The bad silence is TPN. For multiple quarters, the adult TPN program was a pillar — sites added in Turkey, a protocol amendment to loosen exclusion criteria, hope that enrollment would reaccelerate. Thursday's language was terminal in tone: enrollment is “tracking meaningfully behind our original estimated time lines” — Elizabeth Hurlburt, Executive Vice President and Chief Operating Officer · 2026-11-12, and the company will decide on an alternative pathway before the next call. Elizabeth Hurlburt's explanation — “the logistics of running a study in this patient population, are proving to be rather challenging right now” — Elizabeth Hurlburt, Executive Vice President and Chief Operating Officer · 2026-11-12 — is honest, and also an admission that a multi-year pipeline narrative is being retired. One last piece of context: this is not only a CorMedix problem. Renal reimbursement policy is in flux across the market — Kidney Care National Plan surfaced among global top keywords this quarter via other dialysis-exposed reporters, and policy reforms ranked in the global top 25. CorMedix is not swimming against a current; it is standing in one. The difference is that the other operators get paid for the water.